The Maldives Food and Drug Authority (MFDA) has issued another public advisory following an alert from India's drug regulatory body, the Central Drugs Standard Control Organisation (CDSCO), which flagged quality issues with 16 medications.
MFDA has conducted an evaluation to verify whether any of these medications have been imported into the Maldives. Although none were found to have entered the country through official channels, the Authority is urging the public to exercise caution.
List of Medications Identified in the Alert
- Pulmosil (Sildenafil Injection)
- Pantocid (Pantoprazole Tablets IP)
- Ursocol 300 (Ursodeoxycholic Acid Tablets IP)
- Telma H (Telmisartan 40 mg and Hydrochlorothiazide 12.5 mg Tablets IP)
- Defcort 6 (Deflazacort Tablets)
- Paziva-40
- Pantomed-40
- Cefiximine Oral Suspension IP (Dry Syrup)
- Moxymed CV
- Frusemide Injection IP 20 mg
- Kudajarishtam
- Nodosis Tablets
- Haridrakhandam
- Pantoprazole Inj. BP 40 mg
- Yogaraja Guggulu
- PANCEF-OF
Previous Advisory and Enhanced Inspections
This follows a similar advisory from MFDA issued just yesterday regarding 48 additional medications manufactured in India. These were deemed either substandard, spurious, adulterated, or misbranded.
In response, the MFDA has announced plans to reinforce inspections at entry points where medicines are brought into the Maldives.
“As a precautionary measure, we will continue to strengthen inspections at ports importing drugs into Maldives and take all necessary measures to prevent the entry of such drugs,” the MFDA stated in its alert.
Public Encouraged to Contact MFDA
The public is encouraged to contact MFDA at 7200321 for further information or concerns about specific medications.
